Janus Henderson Investors, an investment management company, released its “Janus Henderson Enterprise Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -2.84% in the second quarter, compared to the Russell Midcap Growth Index’s -3.21% return. The firm is committed to a disciplined, risk-aware investment approach that considers fundamentals and relative valuations. In addition, please check the fund’s top five holdings to know its best picks in 2024.
Janus Henderson Enterprise Fund highlighted stocks like Boston Scientific Corporation (NYSE:BSX), in the Q2 2024 investor letter. Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices for use in various interventional medical specialties. The one-month return of Boston Scientific Corporation (NYSE:BSX) was 1.91%, and its shares gained 57.83% of their value over the last 52 weeks. On September 27, 2024, Boston Scientific Corporation (NYSE:BSX) stock closed at $83.35 per share with a market capitalization of $122.744 billion.
Janus Henderson Enterprise Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q2 2024 investor letter:
“Medical device company Boston Scientific Corporation (NYSE:BSX) was another contributor. The stock rose on excitement over the company’s U.S. launch of FARAPULSE, a state-of-the-art pulsed field ablation system that treats atrial fibrillation with less damage to surrounding tissues relative to previous therapies. Boston Scientific is currently the only provider of this technology, which taps into a large and growing addressable market. Even beyond our excitement around FARAPULSE, we continue to like Boston Scientific for its diversified product portfolio, which has provided many potential drivers of revenue growth.”
A surgeon examining a patient’s brain in an operating room, paramedics nearby.
Boston Scientific Corporation (NYSE:BSX) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 82 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the second quarter which was 72 in the previous quarter. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed Boston Scientific Corporation (NYSE:BSX) and shared the list of best dialysis and kidney disease stocks to buy. Boston Scientific Corporation (NYSE:BSX) contributed to the performance on Baron Health Care Fund in Q2 2024. In addition, please check out our hedge fund investor letters Q2 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.